BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:EHL Bio readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies EHL Bio's drugs run\, from Clinic
 alTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07377838-1277@assetmemo.bio
DTSTAMP:20261121T005854Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:ADSTEM: Phase 3 readout est. (NCT07377838)
DESCRIPTION:ADSTEM\, phase 3\, Atopic Dermatitis.\nStudy: Study of ADSTEM I
 njection for Patients With Moderate to Severe Subacute and Chronic Atopic 
 Dermatitis\nEstimated primary completion: September 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/adstem#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07377838
URL:https://assetmemo.bio/drug/adstem#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
